Efavirenz (Monograph)
Brand name: Sustiva
Drug class: HIV Nonnucleoside Reverse Transcriptase Inhibitors
- Reverse Transcriptase Inhibitors
VA class: AM800
Chemical name: (±)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
Molecular formula: C14H9ClF3NO2
CAS number: 154635-17-3
Efavirenz is also contained as an ingredient in the following combinations:
Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate
Warning
- Fixed Combinations
-
If using efavirenz/emtricitabine/tenofovir DF (Atripla), consider that lactic acidosis and severe hepatomegaly with steatosis, including fatalities, have been reported in patients receiving HIV nucleoside reverse transcriptase inhibitors (NRTIs) in conjunction with other antiretrovirals.232
-
If using efavirenz/emtricitabine/tenofovir DF (Atripla), consider that severe, acute exacerbations of HBV have been reported following discontinuance of emtricitabine or tenofovir DF in HIV-infected patients coinfected with HBV.232 The fixed combination is not labeled by FDA for treatment of chronic HBV infection; safety and efficacy not established in HIV-infected patients coinfected with HBV.232 Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months after the fixed combination is discontinued in coinfected patients.232 If appropriate, initiation of HBV treatment may be warranted.232
Introduction
Antiretroviral; HIV nonnucleoside reverse transcriptase inhibitor (NNRTI).1 2 3 12 14
Uses for Efavirenz
Treatment of HIV Infection
Treatment of HIV-1 infection in adults, adolescents, and pediatric patients ≥3 months of age weighing ≥3.5 kg;1 2 10 11 12 200 201 usually used in conjunction with 2 NRTIs.1
For initial treatment in antiretroviral-naive adults and adolescents, experts state that efavirenz in conjunction with tenofovir alafenamide and emtricitabine or efavirenz in conjunction with tenofovir disoproxil fumarate (tenofovir DF) and emtricitabine (or lamivudine) are alternative NNRTI-based regimens.200 Efavirenz in conjunction with abacavir and lamivudine (or emtricitabine) is another NNRTI-based regimen option for initial treatment in adults and adolescents when recommended or alternative regimens cannot be used, but use only in those with baseline plasma HIV RNA levels <100,000 copies/mL who are human leukocyte antigen (HLA)-B*5701 negative.200
For initial treatment in antiretroviral-naive pediatric patients, experts state that efavirenz and 2 NRTIs is a preferred regimen for initial treatment in children ≥3 to <12 years of age and an alternative regimen for initial treatment in adolescents ≥12 years of age who are not sexually mature.201 Efavirenz is not recommended for initial treatment in those 3 months to <3 years of age.201
Usually avoid efavirenz in pregnant women during first trimester;1 avoid in women of childbearing age who may become pregnant.1 202 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
Efavirenz/emtricitabine/tenofovir DF fixed combination (Atripla) can be used in adults, adolescents, and children ≥12 years of age weighing ≥40 kg to decrease pill burden and improve adherence;232 used alone as a complete treatment regimen or used in conjunction with other antiretrovirals.232
Postexposure Prophylaxis following Occupational Exposure to HIV (PEP)
Postexposure prophylaxis of HIV infection following occupational exposure† [off-label] (PEP) in health-care personnel and others exposed via percutaneous injury (e.g., needlestick, cut with sharp object) or mucous membrane or nonintact skin (e.g., chapped, abraded, dermatitis) contact with blood, tissue, or other body fluids that might contain HIV.199
USPHS recommends 3-drug regimen of raltegravir in conjunction with emtricitabine and tenofovir DF as the preferred regimen for PEP following occupational exposures to HIV.199 Efavirenz and 2 NRTIs can be considered an alternative regimen, but use for PEP only with expert consultation.199 Preferred dual NRTI option for PEP regimens is emtricitabine and tenofovir DF (may be given as emtricitabine/tenofovir DF; Truvada); alternative dual NRTIs are tenofovir DF and lamivudine, lamivudine and zidovudine (may be given as lamivudine/zidovudine; Combivir), or zidovudine and emtricitabine.199
Management of occupational exposures to HIV is complex and evolving; consult infectious disease specialist, clinician with expertise in administration of antiretroviral agents, and/or National Clinicians’ Postexposure Prophylaxis Hotline (PEPline at 888-448-4911) whenever possible.199 Do not delay initiation of PEP while waiting for expert consultation.199
Postexposure Prophylaxis following Nonoccupational Exposure to HIV (nPEP)
Postexposure prophylaxis of HIV infection following nonoccupational exposure† [off-label] (nPEP) in individuals exposed to blood, genital secretions, or other potentially infectious body fluids that might contain HIV when the exposure represents a substantial risk for HIV transmission.198 Used in conjunction with other antiretrovirals.198
When nPEP indicated in adults and adolescents ≥13 years of age with normal renal function, CDC states preferred regimen is either raltegravir or dolutegravir used in conjunction with emtricitabine and tenofovir DF (given as emtricitabine/tenofovir DF; Truvada);198 recommended alternative in these patients is ritonavir-boosted darunavir used in conjunction with emtricitabine/tenofovir DF (Truvada).198
CDC states efavirenz is an alternative antiretroviral that can be used in nPEP regimens, but use in such regimens only with expert consultation.198
Consult infectious disease specialist, clinician with expertise in administration of antiretroviral agents, and/or the National Clinicians’ Postexposure Prophylaxis Hotline (PEPline at 888-448-4911) if nPEP indicated in certain exposed individuals (e.g., pregnant women, children, those with medical conditions such as renal impairment) or if considering a regimen not included in CDC guidelines, source virus is known or likely to be resistant to antiretrovirals, or healthcare provider is inexperienced in prescribing antiretrovirals.198 Do not delay initiation of nPEP while waiting for expert consultation.198
Related/similar drugs
Biktarvy, Descovy, Truvada, tenofovir, emtricitabine, abacavir, Atripla
Efavirenz Dosage and Administration
Administration
Oral Administration
Administer efavirenz (Sustiva) or efavirenz/emtricitabine/tenofovir DF (Atripla) orally once daily on an empty stomach, preferably at bedtime.1 232
Administration at bedtime may make adverse CNS effects (dizziness, insomnia, impaired concentration, somnolence, abnormal dreams) more tolerable.1 232
Efavirenz (Sustiva): Use in conjunction with other antiretrovirals.1
Efavirenz/emtricitabine/tenofovir DF (Atripla): Use alone as a complete treatment regimen or use in conjunction with other antiretrovirals.232 Because antiretrovirals in the fixed combination also are available in single-entity or other fixed-combination preparations, take care to ensure that therapy is not duplicated if used in conjunction with other antiretrovirals.232 (See Use of Fixed Combinations under Cautions.)
Do not use single-entity efavirenz (Sustiva) and efavirenz/emtricitabine/tenofovir DF (Atripla) concomitantly, unless needed for adjustment of efavirenz dosage (e.g., when fixed combination used concomitantly with rifampin).1 232
Capsules (Sustiva)
Swallow capsules whole on an empty stomach.1
For adults and pediatric patients ≥3 months of age not able to swallow capsules or tablets, administer capsule contents by mixing with small amount (1–2 teaspoonfuls) of soft food (capsule sprinkle method).1 Consider mixing with infant formula only if infant cannot consume solid foods.1 Administer efavirenz mixture within 30 minutes after preparation; do not consume any additional food or infant formula for 2 hours after the mixture.1
Mixing capsule contents into food: Add 1–2 teaspoonfuls of age-appropriate soft food (e.g., applesauce, grape jelly, yogurt) to a small container.1 Hold appropriate number of capsules (see Table 1) horizontally over the small container, twist open, and empty onto the food.1 Gently mix with a spoon; feed entire mixture to patient.1 Then, add additional 2 teaspoonfuls of soft food to the small container, stir to disperse remaining efavirenz residue, and feed to patient.1
Mixing capsule contents into infant formula: Add 10 mL (2 teaspoonfuls) of reconstituted room temperature infant formula to a 30-mL medicine cup.1 Hold appropriate number of capsules (see Table 1) horizontally over the medicine cup, twist open, and empty onto the formula.1 Gently mix with small spoon.1 Draw up infant formula mixture into 10-mL oral dosing syringe; administer into infant's right or left inner cheek.1 Then, add additional 2 teaspoonfuls of infant formula to the medicine cup, stir to disperse remaining efavirenz residue, draw up into oral dosing syringe, and administer to infant.1
Tablets (Sustiva, Atripla)
Swallow tablets whole on an empty stomach; do not break or crush.1
Dosage
Pediatric Patients
Treatment of HIV Infection
Oral
Efavirenz (Sustiva): Dosage in children ≥3 months of age weighing 3.5 to <40 kg is based on weight.1 (See Table 1.) Adolescents and children weighing ≥40 kg may receive usual adult dosage.1
Weight in kg |
Efavirenz Dosage |
Number of Capsules or Tablets |
---|---|---|
3.5 to <5 |
100 mg once daily |
Two 50-mg capsules |
5 to <7.5 |
150 mg once daily |
Three 50-mg capsules |
7.5 to <15 |
200 mg once daily |
One 200-mg capsule |
15 to <20 |
250 mg once daily |
One 200-mg and one 50-mg capsule |
20 to <25 |
300 mg once daily |
One 200-mg and two 50-mg capsules |
25 to <32.5 |
350 mg once daily |
One 200-mg and three 50-mg capsules |
32.5 to <40 |
400 mg once daily |
Two 200-mg capsules |
≥40 |
600 mg once daily |
One 600-mg tablet or three 200-mg capsules |
Efavirenz/emtricitabine/tenofovir DF (Atripla) in children ≥12 years of age weighing ≥40 kg: 1 tablet (600 mg of efavirenz, 200 mg of emtricitabine, and 300 mg of tenofovir DF) once daily.232
Adults
Treatment of HIV Infection
Oral
Efavirenz (Sustiva): 600 mg once daily.1
Efavirenz/emtricitabine/tenofovir DF (Atripla): 1 tablet (efavirenz 600 mg, emtricitabine 200 mg, and tenofovir DF 300 mg) once daily.232
Treatment of HIV Infection in Patients Weighing ≥50 kg Receiving Rifampin
OralEfavirenz (Sustiva): 800 mg once daily.1 (See Specific Drugs and Laboratory Tests under Interactions.)
Efavirenz/emtricitabine/tenofovir DF (Atripla): 1 tablet (efavirenz 600 mg, emtricitabine 200 mg, and tenofovir DF 300 mg) once daily and 200 mg of single-entity efavirenz (Sustiva) once daily to provide total efavirenz dosage of 800 mg daily.232
Postexposure Prophylaxis of HIV following Occupational Exposure† [off-label]
Oral
Efavirenz (Sustiva): 600 mg once daily.199 Use in conjunction with 2 NRTIs (see Postexposure Prophylaxis following Occupational Exposure to HIV under Uses).199
Initiate PEP as soon as possible following occupational exposure to HIV (preferably within hours); continue for 4 weeks, if tolerated.199
Special Populations
Hepatic Impairment
Treatment of HIV Infection
Efavirenz (Sustiva): Dosage adjustments not needed in patients with mild hepatic impairment;1 do not use in those with moderate or severe hepatic impairment.1 (See Hepatic Impairment under Cautions.)
Efavirenz/emtricitabine/tenofovir DF (Atripla): Use usual dosage in patients with mild hepatic impairment; however, caution advised.232 Do not use in those with moderate or severe hepatic impairment.232
Renal Impairment
Treatment of HIV Infection
Efavirenz (Sustiva): Dosage adjustments not needed.200
Efavirenz/emtricitabine/tenofovir DF (Atripla): Use usual dosage in patients with Clcr ≥50 mL/minute;232 do not use in those with Clcr <50 mL/minute.232
Geriatric Patients
Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1 232
Cautions for Efavirenz
Contraindications
-
Efavirenz and efavirenz/emtricitabine/tenofovir DF: History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.1 232
-
Efavirenz/emtricitabine/tenofovir DF: Consider contraindications associated with each drug in the fixed combination.232
Warnings/Precautions
Interactions
Efavirenz plasma concentrations may be altered if CYP3A substrates, inhibitors, or inducers used concomitantly.1 In addition, efavirenz may alter plasma concentrations of drugs metabolized by CYP3A or 2B6.1 (See Interactions.)
Psychiatric Symptoms
Serious adverse psychiatric symptoms (severe depression, suicidal ideation, nonfatal suicide attempts, aggressive behavior, paranoid reactions) reported rarely in efavirenz clinical studies.1 232
Depression, anxiety, and nervousness also reported in clinical studies.1 Although causal relationship not established, there have been occasional postmarketing reports of delusions, psychosis-like behavior, catatonia, and death by suicide in patients receiving efavirenz.1 Aggressive reactions,1 agitation,1 emotional lability,1 mania,1 neurosis,1 and paranoia1 also reported during postmarketing surveillance.
Factors associated with increased occurrence of psychiatric symptoms include history of injection drug use, history of psychiatric disorders, and treatment with antipsychotic drugs at study entry.1 232
If serious psychiatric adverse events occur, evaluate to determine if symptoms are related to efavirenz; if so, determine whether risks of continued efavirenz outweigh benefits.1 232
Nervous System Effects
Dizziness or insomnia reported frequently; abnormal dreams, hallucinations, or impaired concentration also reported.1 These adverse effects generally begin during first 1–2 days of therapy, improve with continued therapy, and usually resolve after first 2–4 weeks.1
Seizures reported,1 generally in those with a history of seizures.1 Use with caution in patients with history of seizures.1 Monitor anticonvulsant plasma concentrations if used in patients receiving anticonvulsants that are metabolized principally by the liver (e.g., phenytoin, phenobarbital).1 (See Specific Drugs and Laboratory Tests under Interactions.)
Fetal/Neonatal Morbidity and Mortality
May cause fetal harm if administered during first trimester of pregnancy.1 232 Teratogenicity demonstrated in animals.1 Birth defects (including neural tube defects) reported in humans, usually with first-trimester exposure.1 (See Pregnancy under Cautions.)
Advise women of childbearing potential about the teratogenic potential of efavirenz;1 232 perform test to rule out pregnancy before initiating efavirenz or fixed combination containing efavirenz.1 232
Avoid pregnancy during therapy and for 12 weeks after discontinuance of efavirenz or fixed combination containing efavirenz.1 232 Women of childbearing potential should use a reliable method of barrier contraception in addition to or instead of a hormonal contraceptive (oral or other hormonal contraceptive).1 200 202 232 (See Specific Drugs and Laboratory Tests under Interactions.)
Dermatologic and Sensitivity Reactions
Rash (maculopapular skin eruptions) reported frequently.1 2 Pruritus; rash associated with blistering, moist desquamation, or ulceration; allergic reaction; photoallergic dermatitis; erythema multiforme; and Stevens-Johnson syndrome also reported.1 2
Median time to rash onset 11 days in adults and 28 days in pediatric patients; median duration 16 days.1 Mild to moderate rash generally resolves within 1 month with continued efavirenz.1 May be reinitiated after temporary interruption for rash.1 Antihistamines and/or corticosteroids may improve tolerability and hasten resolution of rash.1
Discontinue in patients with life-threatening cutaneous reactions (e.g., Stevens-Johnson syndrome) and consider alternative therapy.1 232
Discontinue in patients with serious rash (e.g., rash associated with blistering, desquamation, mucosal involvement, or fever).1
Hepatotoxicity
Substantial increases in serum AST or ALT concentrations (>5 times ULN) reported in clinical studies in HIV-infected patients coinfected with HBV and/or HCV.1
Hepatic failure and hepatitis reported, some with a fulminant course requiring transplantation or resulting in death.1 Hepatic failure has occurred in some patients with no preexisting hepatic disease or other identifiable risk factors.1
Use with caution in patients with hepatic impairment.1 232 (See Hepatic Impairment under Cautions.)
Assess serum liver enzyme concentrations prior to and during efavirenz treatment in patients with underlying hepatic disease (including those with HBV and/or HCV infection), patients with markedly increased serum transaminase concentrations, and patients receiving other drugs associated with liver toxicity.1 232
Also consider monitoring serum liver enzymes in patients without preexisting hepatic dysfunction or other risk factors.1 232
In patients with serum hepatic enzyme concentrations >5 times ULN, consider whether benefits of continued efavirenz therapy outweigh risks of hepatotoxicity.1 232
Use of Fixed Combinations
Efavirenz/emtricitabine/tenofovir DF: Consider cautions, precautions, contraindications, and interactions associated with each drug in the fixed combination.232 Consider cautionary information applicable to specific populations (e.g., pregnant or nursing women, individuals with hepatic or renal impairment, geriatric patients) for each drug.232
Do not use efavirenz/emtricitabine/tenofovir DF concomitantly with single-entity efavirenz, unless needed for adjustment of efavirenz dosage (e.g., when fixed combination used concomitantly with rifampin).1 232 (See Specific Drugs and Laboratory Tests under Interactions.)
Because the antiretrovirals contained in efavirenz/emtricitabine/tenofovir DF also are available in single-entity or other fixed-combination preparations, take care to ensure that therapy is not duplicated if the fixed combination is used in conjunction with other antiretrovirals.232
Do not use efavirenz/emtricitabine/tenofovir DF concomitantly with any preparation containing emtricitabine or tenofovir DF.232 In addition, do not use concomitantly with any preparation containing lamivudine or with adefovir.232
Cardiovascular and Lipid Effects
Prolongation of QT interval corrected for rate (QTc) reported.1 Consider alternative antiretroviral in patients at increased risk of torsades de pointes and in those receiving a drug known to increase risk of torsades de pointes.1 (See Interactions.)
Increased serum concentrations of total cholesterol and triglycerides reported.1 Assess serum cholesterol and triglycerides prior to and periodically during therapy.1
Adipogenic Effects
Redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement (“buffalo hump”), peripheral wasting, breast enlargement, and general cushingoid appearance, reported in patients receiving antiretroviral therapy.1
Mechanism and long-term consequences of fat redistribution unknown;1 causal relationship not established.1
Immune Reconstitution Syndrome
During initial treatment, HIV-infected patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium complex [MAC], M. tuberculosis, cytomegalovirus [CMV], Pneumocystis jirovecii [formerly P. carinii]);1 this may necessitate further evaluation and treatment.1
Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) also reported in the setting of immune reconstitution;1 time to onset is more variable and can occur many months after initiation of antiretroviral therapy.1
Specific Populations
Pregnancy
Efavirenz may cause fetal harm if administered during first trimester of pregnancy.1 232 There are retrospective case reports of neural tube defects in infants born to mothers with first trimester exposure to efavirenz,1 but prospective pregnancy data not sufficient to adequately assess this risk.1 202
Efavirenz/emtricitabine/tenofovir DF (Atripla): Category D.232
Antiretroviral Pregnancy Registry at 800-258-4263 or [Web].1 202
Data from the Antiretroviral Pregnancy Registry show no difference in the risk of overall birth defects for efavirenz compared with background rate for birth defects.1
Women of childbearing potential should use effective contraceptive measures during therapy and for 12 weeks after discontinuance of efavirenz or efavirenz/emtricitabine/tenofovir DF.1 232 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
Manufacturer states avoid use during first trimester of pregnancy.1
Experts state efavirenz in conjunction with 2 NRTIs is an alternative NNRTI-based regimen for initial treatment in antiretroviral-naive pregnant women,202 but may be a preferred NNRTI-based regimen for initial treatment when drug interactions with PI-based regimens are a concern or when the convenience of a fixed-combination, single-tablet, once-daily regimen is advantageous.202 However, these experts state efavirenz should be avoided during first 8 weeks of pregnancy.202
Experts also state that antiretroviral regimens that do not include efavirenz should be strongly considered in women who are planning to become pregnant or are sexually active and not using effective contraception, provided such regimens are acceptable to the provider and not expected to compromise the health of the woman.202
If a pregnant woman already receiving an efavirenz-containing regimen presents for antenatal care during first trimester, some experts suggest the regimen can be continued if well tolerated and providing adequate virologic suppression.202 This strategy recognizes that risk of neural tube defects is limited to first 5–6 weeks of pregnancy and pregnancy rarely recognized until after 4–6 weeks and that unnecessary changes in antiretroviral regimens during pregnancy may be associated with loss of virologic control and increased risk of perinatal HIV transmission.202
If efavirenz or a fixed combination containing efavirenz is used during first trimester or if pregnancy occurs, apprise patient of potential harm to the fetus.1 232
Lactation
Efavirenz distributed into human milk.202
Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.1 202 232
Pediatric Use
Efavirenz (Sustiva): Safety and efficacy not evaluated in neonates and infants <3 months of age or who weigh <3.5 kg;1 not recommended in these pediatric patients.1 201 Some experts state efavirenz not recommended for initial treatment in antiretroviral-naive pediatric patients 3 months to <3 years of age.201
Efavirenz/emtricitabine/tenofovir DF (Atripla): Safety and efficacy not established in pediatric patients <12 years of age or weighing <40 kg.232
Adverse effects reported with efavirenz in pediatric patients 3 months to 21 years of age are similar to those reported in adults with the exception of rash.1 Rash reported more frequently in children than adults and the incidence of moderate to severe rash has been greater in children than adults.1
Not recommended in sexually active adolescent females of childbearing potential who desire to become pregnant or when reliable contraception cannot be ensured.201 (See Pregnancy under Cautions.)
Geriatric Use
Insufficient experience in those ≥65 years of age to determine whether they respond differently than younger adults.1 232
Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1 232
Hepatic Impairment
Efavirenz (Sustiva): Use with caution in mild hepatic impairment;1 do not use in moderate or severe hepatic impairment.1
Efavirenz/emtricitabine/tenofovir DF (Atripla): Use with caution in mild hepatic impairment;232 do not use in moderate or severe hepatic impairment.232
Monitor hepatic enzyme concentrations in patients with known or suspected HBV or HCV infection, patients with substantially increased transaminase concentrations, and in patients receiving other drugs associated with hepatotoxicity.1 (See Hepatotoxicity under Cautions.)
Renal Impairment
Efavirenz (Sustiva): Pharmacokinetics not specifically studied; clinically important decreases in clearance not anticipated.1 (See Renal Impairment under Dosage and Administration.)
Efavirenz/emtricitabine/tenofovir DF (Atripla): Do not use in those with Clcr <50 mL/minute.232
Common Adverse Effects
Rash, dizziness, nausea, headache, fatigue, insomnia, vomiting.1
Drug Interactions
Metabolized by CYP3A and CYP2B6.1
Inhibits CYP2C9 and CYP2C19 and, to a lesser extent, CYP2D6 and CYP1A2.1 Does not inhibit CYP2E1.1
Induces CYP3A and CYP2B6.1
The following drug interactions are based on studies using efavirenz.1 Drug interaction studies not performed using efavirenz/emtricitabine/tenofovir DF.232 When fixed combinations are used, consider interactions associated with each drug in the fixed combination.232
Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes
Pharmacokinetic interactions likely with drugs that are inhibitors, inducers, or substrates of CYP isoenzymes 3A, 2B6, 2C9, or 2C19 with possible alteration in metabolism of efavirenz and/or other drug.1
Specific Drugs and Laboratory Tests
Drug |
Interaction |
Comments |
---|---|---|
Abacavir |
Clinically important interactions not expected1 In vitro evidence of additive antiretroviral effects1 |
Dosage adjustments not needed1 |
Alcohol |
Potential for additive CNS effects1 |
|
Antacids (aluminum hydroxide, magnesium hydroxide, simethicone) |
Pharmacokinetic interaction unlikely1 |
Dosage adjustments not needed1 |
Anticoagulants, oral |
Warfarin concentrations likely to be affected1 |
|
Anticonvulsants (carbamazepine, phenobarbital, phenytoin) |
Carbamazepine: Decreased concentrations and AUCs of efavirenz and carbamazepine1 200 Phenobarbital, phenytoin: Possible decreased concentrations of phenobarbital and phenytoin and/or efavirenz1 200 |
Carbamazepine: Data insufficient to make dosage recommendations for concomitant use with efavirenz;1 use with caution and monitor anticonvulsant concentrations;1 200 consider alternative anticonvulsant200 Phenobarbital, phenytoin: Use caution and monitor anticonvulsant concentrations if used with efavirenz;1 200 consider alternative anticonvulsant200 Efavirenz/emtricitabine/tenofovir DF: Data insufficient to make dosage recommendations for concomitant use with carbamazepine;232 use alternative anticonvulsant232 |
Antifungals, azoles (fluconazole, isavuconazonium, itraconazole, ketoconazole, posaconazole, voriconazole) |
Fluconazole: No clinically important pharmacokinetic interactions1 200 Isavuconazonium (prodrug of isavuconazole): Possible decreased isavuconazole concentrations200 Itraconazole: Decreased concentrations of itraconazole; no change in efavirenz concentrations1 Ketoconazole: Possible decreased concentrations of the antifungal1 Posaconazole: Decreased posaconazole concentrations and AUC;1 200 does not affect efavirenz concentrations200 Voriconazole: Decreased voriconazole concentrations; increased efavirenz concentrations1 200 |
Fluconazole: Dosage adjustments not needed1 Isavuconazonium: Consider monitoring isavuconazole concentrations and antifungal efficacy;200 isavuconazonium dosage adjustments may be needed200 Itraconazole: Dosage recommendation for concomitant use not available;1 consider alternative antifungal;1 experts state avoid concomitant use;200 if used concomitantly, closely monitor itraconazole concentrations and adjust antifungal dosage accordingly200 Posaconazole: Avoid concomitant use unless potential benefits outweigh risks;1 200 if used concomitantly, monitor posaconazole concentrations and adjust antifungal dosage accordingly200 Voriconazole: Increase voriconazole maintenance dosage to 400 mg every 12 hours and decrease efavirenz dosage to 300 mg once daily (use efavirenz capsules; do not divide tablet);1 200 do not use usual voriconazole dosage with usual efavirenz dosage;1 200 concomitant use with efavirenz/emtricitabine/tenofovir DF contraindicated232 |
Antihistamines |
Decreased cetirizine concentrations; no change in efavirenz concentrations1 |
When used with cetirizine, dosage adjustments not needed1 |
Antimalarials |
Fixed combination of artemether and lumefantrine (artemether/lumefantrine): Decreased concentrations and AUC of artemether and active metabolite of artemether; decreased lumefantrine AUC; may decrease antimalarial effect of artemether/lumefantrine;1 200 possible QT interval prolongation1 Fixed combination of atovaquone and proguanil (atovaquone/proguanil): Decreased AUC of atovaquone and proguanil;200 |
Artemether/lumefantrine: Consider alternative antimalarial agent;1 200 experts state if used concomitantly, monitor for antimalarial efficacy and malaria recurrence200 Atovaquone/proguanil: Concomitant use not recommended;1 experts state consider alternative for malaria prophylaxis, if possible200 |
Antimycobacterials (bedaquiline, rifabutin, rifampin, rifapentine) |
Bedaquiline: Possible decreased bedaquiline concentrations200 Rifabutin: Decreased rifabutin concentrations; no change in efavirenz AUC1 54 200 |
Bedaquiline: Concomitant use not recommended200 Rifabutin: Manufacturer of efavirenz states increase daily rifabutin dosage by 50% and consider doubling rifabutin dosage when given 2 or 3 times weekly; experts suggest increase rifabutin dosage to 450–600 mg once daily or 600 mg 3 times weekly, provided regimen does not include a PI1 200 Rifampin: Manufacturer states increase efavirenz dosage to 800 mg once daily in those weighing ≥50 kg;1 experts recommend efavirenz 600 mg once daily for patients weighing <60 kg and efavirenz 800 mg once daily in those weighing >60 kg and state virologic response should be monitored and therapeutic drug monitoring considered;200 if using efavirenz/emtricitabine/tenofovir DF, use 1 tablet of fixed combination (see Preparations) and 200 mg of single-entity efavirenz once daily to provide efavirenz dosage of 800 mg daily232 Rifapentine: Do not use concomitantly200 |
Antipsychotics (pimozide) |
Pimozide: Do not use concomitantly200 |
|
Atazanavir |
Ritonavir-boosted atazanavir: Possible increased atazanavir concentrations and AUC depending on specific regimen1 203 Cobicistat-boosted atazanavir: Decreased atazanavir and cobicistat concentrations; no change in efavirenz concentrations200 238 239 Unboosted atazanavir: Substantially decreased atazanavir concentrations and AUC;1 203 no clinically important change in efavirenz concentrations200 No in vitro evidence of antagonistic antiretroviral effects203 |
Ritonavir-boosted atazanavir in treatment-naive adults: Use atazanavir 400 mg and ritonavir 100 mg once daily (with food) and efavirenz 600 mg once daily (without food, preferably at bedtime)1 200 203 Cobicistat-boosted atazanavir in antiretroviral-naive adults: Use single-entity atazanavir 400 mg and single-entity cobicistat 150 mg once daily (with food) and efavirenz 600 mg once daily (without food, preferably at bedtime)200 239 Ritonavir-boosted or cobicistat-boosted atazanavir in antiretroviral-experienced adults: Concomitant use not recommended1 200 203 Unboosted atazanavir: Do not use with efavirenz200 203 Efavirenz/emtricitabine/tenofovir DF: Concomitant use with atazanavir (with or without low-dose ritonavir) not recommended232 |
Atovaquone |
Decreased atovaquone AUC200 |
Consider alternative treatment for Pneumocystis jirovecii pneumonia (PCP) or toxoplasmosis or consider alternative antiretroviral regimen;200 if used concomitantly, monitor for atovaquone efficacy200 |
Avanafil |
Data not available200 |
Concomitant use not recommended200 |
Benzodiazepines |
Midazolam, triazolam: Possible increased midazolam or triazolam concentrations200 Lorazepam: Increased lorazepam concentrations, but no effect on lorazepam AUC1 200 Alprazolam: Data not available200 |
Midazolam (oral), triazolam: Do not use concomitantly200 Midazolam (parenteral): Experts state a single parenteral midazolam dose can be used with caution in a monitored situation for procedural sedation200 Lorazepam: Dosage adjustments not needed1 200 Alprazolam: Monitor for benzodiazepine effectiveness200 |
Buprenorphine |
Buprenorphine (sublingual or buccal): Decreased buprenorphine and norbuprenorphine AUCs200 Buprenorphine (subdermal implant): Data not available200 |
Buprenorphine (sublingual or buccal): Some experts state dosage adjustments not recommended, but monitor for withdrawal symptoms200 Buprenorphine (subdermal implant): If efavirenz initiated after insertion of implant, clinical monitoring recommended200 |
Bupropion |
Decreased bupropion concentrations and AUC;1 200 increased concentrations of hydroxybupropion (an active metabolite)1 |
Titrate bupropion dosage based on clinical response;200 do not exceed maximum recommended bupropion dosage1 |
Calcium-channel blocking agents |
Diltiazem: Decreased diltiazem concentrations;1 slightly increased efavirenz concentrations1 Other calcium-channel blocking agents that are substrates of CYP 3A4 (e.g., felodipine, nicardipine, nifedipine, verapamil): Possible decreased concentrations of the calcium-channel blocking agent1 |
Diltiazem: Titrate diltiazem dosage based on clinical response;1 200 232 adjustment of efavirenz or efavirenz/emtricitabine/tenofovir DF dosage not needed1 232 Other calcium-channel blocking agents that are substrates of CYP 3A4: Titrate dosage of calcium-channel blocking agent according to clinical response1 200 |
Cisapride |
Do not use concomitantly200 |
|
Corticosteroids |
Dexamethasone: Possible decreased efavirenz concentrations200 |
Dexamethasone: Monitor virologic response;200 consider alternative corticosteroids for long-term use200 |
Daclatasvir |
||
Darunavir |
Ritonavir-boosted darunavir: Increased efavirenz AUC; decreased darunavir AUC;200 204 clinical importance unknown200 Cobicistat-boosted darunavir: Possible decreased darunavir and cobicistat concentrations;200 239 possible loss of therapeutic effect and development of resistance to darunavir239 No in vitro evidence of antagonistic antiretroviral effects204 |
Ritonavir-boosted darunavir: Usual dosage can be used;204 some experts recommend close monitoring;200 consider monitoring plasma concentrations of darunavir and efavirenz200 Cobicistat-boosted darunavir: Concomitant use not recommended200 239 |
Delavirdine |
||
Didanosine |
In vitro evidence of additive antiretroviral effects1 |
Efavirenz/emtricitabine/tenofovir DF: Use concomitantly with caution and monitor closely for didanosine-associated adverse effects (e.g., pancreatitis, lactic acidosis, neuropathy)232 |
Dolutegravir |
Decreased dolutegravir concentrations and AUC;200 236 effect on efavirenz pharmacokinetics unlikely236 No in vitro evidence of antagonistic antiretroviral effects236 |
Adults: In antiretroviral-naive or antiretroviral-experienced, HIV integrase strand transferase inhibitor-naive (INSTI-naive), use dolutegravir 50 mg twice daily;200 236 in INSTI-experienced with documented or suspected INSTI resistance, consider alternative to efavirenz whenever possible200 236 Pediatric patients: In antiretroviral-naive or antiretroviral-experienced, INSTI-naive weighing 30 kg to <40 kg, use dolutegravir 35 mg twice daily;236 in those weighing ≥40 kg, use dolutegravir 50 mg twice daily;1 in INSTI-experienced with documented or suspected INSTI resistance, consider alternative to efavirenz whenever possible236 |
Elbasvir and grazoprevir |
Fixed combination of elbasvir and grazoprevir (elbasvir/grazoprevir): Substantially decreased elbasvir and grazoprevir concentrations;177 200 no clinically important effect on efavirenz concentrations;177 200 possible loss of virologic response to elbasvir/grazoprevir 177 |
Elbasvir/grazoprevir: Concomitant use contraindicated177 200 |
Elvitegravir |
Cobicistat-boosted elvitegravir: Possible altered concentrations of elvitegravir, cobicistat, and efavirenz200 |
Cobicistat-boosted elvitegravir: Do not use concomitantly200 |
Emtricitabine |
Clinically important interactions not expected1 In vitro evidence of additive antiretroviral effects1 |
Dosage adjustments not needed1 |
Enfuvirtide |
In vitro evidence of additive to synergistic antiretroviral effects1 223 |
|
Ergot alkaloids (dihydroergotamine, ergotamine, methylergonovine) |
Possible decreased ergot alkaloid concentrations; possible inadequate treatment effect202 |
Do not use concomitantly200 If methylergonovine used to treat postpartum hemorrhage in a woman receiving efavirenz, additional uterotonic agents may be needed202 |
Estrogens/Progestins |
Oral hormonal contraceptive containing ethinyl estradiol and norgestimate: Substantially decreased concentrations and AUC of norelgestromin and levonorgestrel (metabolites of norgestimate);1 76 200 202 no effect on peak concentrations or AUC of ethinyl estradiol; no effect on efavirenz concentrations76 Etonogestrel (subcutaneous implant): Not studied, but decreased etonogestrel concentrations expected;1 202 subcutaneous implant contraceptive failure reported in women receiving efavirenz1 202 Levonorgestrel (subcutaneous implant): Decreased levonorgestrel concentrations;78 unintended pregnancies reported78 79 200 |
Hormonal contraceptives (oral or other hormonal contraceptives): Use a barrier contraceptive as an alternative to or in addition to hormonal contraceptive in women of childbearing potential during and for 12 weeks after efavirenz therapy is discontinued1 200 202 Levonorgestrel (oral): Efficacy as emergency contraceptive expected to be decreased in women receiving efavirenz77 202 |
Etravirine |
Decreased etravirine concentrations and loss of therapeutic effect200 214 |
|
Fosamprenavir |
Substantially decreased concentrations of amprenavir (active metabolite of fosamprenavir) if used with fosamprenavir (without low-dose ritonavir);1 205 additional pharmacokinetic interactions if used with ritonavir-boosted fosamprenavir205 In vitro evidence of synergistic antiretroviral effects205 |
Fosamprenavir (without low-dose ritonavir): Appropriate dosages for concomitant use with efavirenz or efavirenz/emtricitabine/tenofovir DF with respect to safety and efficacy not established1 205 232 Ritonavir-boosted fosamprenavir: Use usual efavirenz dosage with fosamprenavir 1.4 g once daily and ritonavir 300 mg once daily or, alternatively, with fosamprenavir 700 mg twice daily and ritonavir 100 mg twice daily200 Efavirenz/emtricitabine/tenofovir DF: If once-daily regimen of ritonavir-boosted fosamprenavir used, increase ritonavir dosage to 300 mg once daily;232 if a twice-daily regimen of ritonavir-boosted fosamprenavir used, ritonavir dosage adjustment not needed232 |
Histamine H2-receptor antagonists (famotidine) |
Pharmacokinetic interaction unlikely with famotidine1 |
When used with famotidine, dosage adjustments not needed1 |
HMG-CoA reductase inhibitors (statins) |
Atorvastatin, pravastatin, and simvastatin: Decreased concentrations of the antilipemic agent;1 200 no clinically important effect on efavirenz concentrations1 Pitavastatin: Decreased AUC and increased concentrations of pitavastatin200 Rosuvastatin: Data not available200 |
Atorvastatin: Titrate atorvastatin dosage based on lipid response; do not exceed maximum recommended dosage200 Lovastatin: Titrate lovastatin dosage based on lipid response; do not exceed maximum recommended dosage; avoid lovastatin if efavirenz regimen includes a ritonavir-boosted PI200 Pitavastatin: Dosage adjustments not necessary200 Pravastatin: Titrate pravastatin dosage based on lipid response; do not exceed the maximum recommended dosage200 Rosuvastatin: Titrate rosuvastatin dosage based on lipid response; do not exceed maximum recommended dosage200 Simvastatin: Titrate simvastatin dosage based on lipid response; do not exceed maximum recommended dosage;200 avoid simvastatin if efavirenz regimen includes a ritonavir-boosted PI200 |
Immunosuppressive agents (cyclosporine, sirolimus, tacrolimus) |
Cyclosporine, sirolimus, tacrolimus: Possible decreased concentrations of the immunosuppressive agents;1 no effect on efavirenz concentrations1 |
Cyclosporine, sirolimus, tacrolimus: Dosage of immunosuppressive agent may need to be adjusted if used with efavirenz or efavirenz/emtricitabine/tenofovir DF;1 232 whenever efavirenz or efavirenz/emtricitabine/tenofovir DF is initiated or discontinued, monitor immunosuppressive agent concentrations for at least 2 weeks until stable1 232 |
Indinavir |
Decreased indinavir AUC; no clinically important effect on efavirenz concentrations or AUC1 In vitro evidence of additive antiretroviral effects1 |
Optimum dosage for concomitant use not established; increasing indinavir dosage to 1 g every 8 hours does not compensate for increased indinavir metabolism due to efavirenz1 |
Lamivudine |
No effect on lamivudine peak concentrations or AUC1 In vitro evidence of additive antiretroviral effects1 |
Dosage adjustments not needed1 |
Ledipasvir and sofosbuvir |
Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): clinically important pharmacokinetic interactions with efavirenz not expected;181 if used with efavirenz/emtricitabine/tenofovir DF, decreased ledipasvir concentrations but no clinically important effect on sofosbuvir or efavirenz concentrations181 200 |
Ledipasvir/sofosbuvir: Dosage adjustments not needed if used with efavirenz;181 200 if used with efavirenz/emtricitabine/tenofovir DF, monitor for tenofovir-associated adverse effects232 |
Lopinavir/ritonavir |
Decreased lopinavir concentrations and AUC1 207 In vitro evidence of additive antiretroviral effects1 |
Once-daily lopinavir/ritonavir regimen not recommended with efavirenz1 207 If efavirenz used with lopinavir in adults, recommended dosage of lopinavir/ritonavir tablets is lopinavir 500 mg/ritonavir 125 mg twice daily;207 alternatively, recommended dosage of lopinavir/ritonavir oral solution is lopinavir 533 mg/ritonavir 133 mg (6.5 mL) twice daily207 |
Macrolides (azithromycin, clarithromycin, erythromycin) |
Risk of QT interval prolongation1 Azithromycin: Pharmacokinetic interaction unlikely1 Clarithromycin: Decreased clarithromycin concentrations and AUC and increased 14-hydroxyclarithromycin concentrations and AUC1 Erythromycin: Not studied1 |
Consider alternative to macrolide antibiotics1 Azithromycin: Dosage adjustments not needed1 Clarithromycin: Some experts state consider alternative (e.g., azithromycin)200 |
Maraviroc |
Decreased maraviroc concentrations and AUC1 200 224 No in vitro evidence of antagonistic antiretroviral effects224 |
Recommended maraviroc dosage is 600 mg twice daily when used with efavirenz, provided regimen does not include a potent CYP3A inhibitor200 224 |
Methadone |
Decreased methadone concentrations and AUC;1 opiate withdrawal manifestations required 22% increase in methadone dosage1 |
Inform patients of potential interaction; closely monitor for signs of opiate withdrawal; increased methadone maintenance dosage may be necessary1 200 |
Nelfinavir |
Increased nelfinavir concentrations and AUC; decreased efavirenz concentrations and AUC1 208 In vitro evidence of additive to synergistic antiretroviral effects1 208 |
Dosage adjustments not needed1 |
Nevirapine |
Decreased efavirenz concentrations and AUC;200 215 no change in nevirapine concentrations200 Increased incidence of adverse effects;215 no improvement in efficacy215 |
|
Ombitasvir, paritaprevir, and ritonavir |
Fixed combination of ombitasvir, paritaprevir, and ritonavir (ombitasvir/paritaprevir/ritonavir) with or without dasabuvir: Concomitant use poorly tolerated;175 179 180 elevated liver enzymes reported175 179 180 |
Ombitasvir/paritaprevir/ritonavir with or without dasabuvir: Concomitant use contraindicated175 179 180 200 |
Psychotherapeutic agents |
Potential for additive CNS effects1 |
|
Raltegravir |
Decreased raltegravir concentrations and AUC200 225 In vitro evidence of additive to synergistic antiretroviral effects225 |
|
Rilpivirine |
Decreased rilpivirine concentrations226 |
|
Ritonavir |
Increased ritonavir AUC and increased efavirenz AUC1 40 200 In vitro evidence of additive antiretroviral effects1 |
Monitor hepatic enzymes and monitor patient for adverse effects (e.g., dizziness, nausea, paresthesia) if used with efavirenz or efavirenz/emtricitabine/tenofovir DF1 201 232 |
St. John’s wort (Hypericum perforatum) |
Decreased efavirenz concentrations; possible loss of virologic response and increased risk of efavirenz resistance63 64 |
|
Saquinavir |
Decreased saquinavir concentrations and AUC;1 210 decreased efavirenz concentrations and AUC1 210 In vitro evidence of additive antiretroviral effects1 |
Ritonavir-boosted saquinavir: Manufacturer of saquinavir states concomitant use not recommended;210 appropriate dosages with respect to safety and efficacy not established1 210 Some experts state that usual dosage of ritonavir-boosted saquinavir (saquinavir 1 g twice daily and ritonavir 100 mg twice daily) may be used with efavirenz200 |
Selective serotonin-reuptake inhibitors (SSRIs) |
Paroxetine: No clinically important interactions1 Sertraline: Decreased sertraline concentrations and AUC1 |
Paroxetine: Dosage adjustments not needed1 Sertraline: Adjust sertraline dosage based on clinical response1 |
Simeprevir |
Substantially decreased simeprevir concentrations and AUC;187 200 may result in loss of simeprevir therapeutic effect187 No clinically important effect on efavirenz pharmacokinetics187 200 |
|
Sofosbuvir |
No clinically important effect on sofosbuvir pharmacokinetics188 |
Dosage adjustments not needed for either drug188 |
Sofosbuvir and velpatasvir |
Efavirenz/emtricitabine/tenofovir DF): No clinically important effect on pharmacokinetics of sofosbuvir, efavirenz, or emtricitabine;176 decreased velpatasvir concentrations and AUC and increased tenofovir concentrations and AUC176 |
Concomitant use not recommended176 |
Stavudine |
Clinically important interactions not expected1 In vitro evidence of additive antiretroviral effects1 |
Dosage adjustments not needed1 |
Tenofovir DF |
No effect on concentrations or AUCs of either drug1 221 In vitro evidence of additive to synergistic antiretroviral effects1 221 |
Dosage adjustments not needed1 |
Tests for cannabinoids |
False-positive urine cannabinoid test when screening test used;1 efavirenz does not bind cannabinoid receptors1 |
Confirm positive cannabinoid screening test with a more specific test1 |
Tipranavir |
Ritonavir-boosted tipranavir: Decreased tipranavir concentrations and no change in efavirenz concentrations using tipranavir 500 mg twice daily and ritonavir 100 mg twice daily with efavirenz 600 mg once daily200 211 In vitro evidence of additive antiretroviral effects211 |
Experts state dosage adjustments not necessary200 |
Valproic acid |
No evidence of pharmacokinetic interaction75 |
|
Zidovudine |
No effect on zidovudine peak concentrations or AUC1 In vitro evidence of additive antiretroviral effects1 |
Dosage adjustments not necessary1 |
Efavirenz Pharmacokinetics
Absorption
Bioavailability
Peak plasma efavirenz concentrations attained within 3–5 hours.1
Fixed-combination tablet containing efavirenz 600 mg, emtricitabine 200 mg, and tenofovir DF 300 mg (efavirenz/emtricitabine/tenofovir DF; Atripla) is bioequivalent to a 600-mg efavirenz tablet, 200-mg emtricitabine capsule, and 300-mg tenofovir DF tablet taken simultaneously in fasting state.232
Food
Administration with food increases efavirenz bioavailability.1
Compared with administration in the fasting state, AUC increased 22 or 17% when a single 600-mg efavirenz dose as capsules was administered with a high-fat, high-calorie meal (894 kcal, 54 g fat, 54% calories from fat) or a reduced-fat normal calorie meal (440 kcal, 2 g fat, 4% calories from fat), respectively.1
Compared with administration in the fasting state, AUC increased 28% when a single 600-mg efavirenz dose as tablets was administered with a high-fat, high-calorie meal (1000 kcal, 500–600 kcal from fat).1
In healthy adults, 600-mg efavirenz dose administered by opening 200-mg capsules and mixing contents of 3 capsules with 2 teaspoonfuls of soft food (e.g., applesauce, grape jelly, yogurt) or infant formula resulted in efavirenz AUC that met bioequivalency criteria compared with intact capsules administered in fasting state.1
Distribution
Extent
Not fully characterized.1
Low efavirenz concentrations distributed into CSF.1
Animal studies indicate efavirenz crosses placenta in rats, rabbits, and primates.202 Distributed into human milk.202
Plasma Protein Binding
99.5–99.75%.1
Elimination
Metabolism
Metabolized by CYP3A and CYP2B6; undergoes subsequent glucuronidation.1
Elimination Route
16–61% excreted in feces (principally as unchanged drug) and 14–34% eliminated in urine as unchanged drug (<1%) or metabolites.1
Not removed by hemodialysis; probably not removed by peritoneal dialysis.1 67
Half-life
52–76 hours after a single dose and 50–55 hours after multiple doses.1
Special Populations
Hepatic impairment: Pharmacokinetics not affected by mild impairment (Child-Pugh class A);1 data insufficient to determine whether affected by moderate or severe impairment (Child-Pugh class B or C).1
Stability
Storage
Oral
Capsules
Efavirenz (Sustiva): 25°C (may be exposed to 15–30°C).1
Tablets
Efavirenz (Sustiva): 25°C (may be exposed to 15–30°C).1
Efavirenz/emtricitabine/tenofovir DF (Atripla): 25°C (may be exposed to 15–30°C).232
Actions and Spectrum
-
Pharmacologically related to other NNRTIs (e.g., delavirdine, etravirine, nevirapine, rilpivirine); differs structurally from these drugs; also differs pharmacologically and structurally from other currently available antiretrovirals.1 2 3 6 12 14 52 53 212 215
-
Inhibits replication of HIV-1 by interfering with viral RNA- and DNA-directed polymerase activities of reverse transcriptase.1 3
-
HIV-1 with reduced susceptibility to efavirenz have been selected in vitro and have emerged during therapy with the drug.1 3 9 14 18 18
-
Strains of HIV-1 resistant to efavirenz may be cross-resistant to some other NNRTIs (e.g., delavirdine, nevirapine).3 9 10 18 32 50 200 201 1 215
-
Cross-resistance between efavirenz and NRTIs unlikely since the drugs bind at difference sites on reverse transcriptase and have difference mechanisms of action.1 3 9 10 32 Cross-resistance between efavirenz and PIs unlikely since the drugs have different target enzymes and mechanisms of action.1 32
Advice to Patients
-
Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician.1 232 Importance of taking as prescribed; do not alter or discontinue antiretroviral regimen without consulting clinician.1 232
-
Importance of using efavirenz in conjunction with other antiretrovirals—not for monotherapy.1 Efavirenz/emtricitabine/tenofovir DF (Atripla) can be used alone as a complete treatment regimen or can be used in conjunction with other antiretrovirals.232
-
Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur.1 232
-
Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others.200 Importance of continuing to practice safer sex (e.g., using latex or polyurethane condoms to minimize sexual contact with body fluids), never sharing personal items that can have blood or body fluids on them (e.g., toothbrushes, razor blades), and never reusing or sharing needles.1 200
-
Importance of reading patient information provided by the manufacturer.1 232
-
Importance of taking efavirenz on an empty stomach, preferably at bedtime.1 232
-
In patients not able to swallow capsules or tablets, importance of patient or caregiver reading and carefully following instructions for mixing and administering capsule contents in small amount of soft food or infant formula.1
-
If a dose is missed, patient should take the missed dose as soon as it is remembered, unless it is almost time for next dose.1 If a dose is missed, do not take a double dose to make up for missed dose.1
-
Advise patients that adverse CNS effects (e.g., dizziness, insomnia, impaired concentration, drowsiness, abnormal dreams) are common during first weeks of efavirenz therapy.1 232 Taking the drug at bedtime may improve tolerability.1 Additive effects may occur if used with alcohol or psychoactive drugs.1 232 If CNS effects occur, avoid potentially hazardous tasks such as driving or operating machinery.1 232
-
Advise patients that serious psychiatric symptoms (e.g., severe depression, suicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms) have occurred.1 232 Importance of informing clinician of any history of mental illness or substance abuse.1 232 Importance of seeking immediate medical evaluation if severe psychiatric symptoms occur.1 232
-
Risk of rash.1 232 Since rash may be serious, importance of promptly contacting clinician if rash occurs.1 232
-
Redistribution/accumulation of body fat may occur, with as yet unknown long-term health effects.1 232
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products, and any concomitant illnesses.1 232
-
Importance of women using a reliable barrier method of contraception instead of or in addition to a hormonal contraceptive (oral or other hormonal contraceptive) during and for 12 weeks after efavirenz therapy.1 232
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 232 Advise HIV-infected women not to breast-feed.1 232
-
Importance of advising patients of other important precautionary information.1 232 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Capsules |
50 mg |
Sustiva |
Bristol-Myers Squibb |
200 mg |
Sustiva |
Bristol-Myers Squibb |
||
Tablets, film-coated |
600 mg |
Sustiva |
Bristol-Myers Squibb |
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets, film-coated |
600 mg with Emtricitabine 200 mg and Tenofovir Disoproxil Fumarate 300 mg |
Atripla |
Bristol-Myers Squibb and Gilead |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions May 15, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Bristol-Myers Squibb. Sustiva (efavirenz) capsules and tablets prescribing information. Princeton, NJ; 2017 Jan.
2. Adkins JC, Noble S. Efavirenz. Drugs. 1998; 56:1055-64. http://www.ncbi.nlm.nih.gov/pubmed/9878993?dopt=AbstractPlus
3. Young SD, Britcher SF, Tran LE et al. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother. 1995; 39:2602-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=162996&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/8592986?dopt=AbstractPlus
4. Rabel SR, Maurin MB, Rowe SM et al. Determination of the pKa and pH-solubility behavior of an ionizable cyclic carbamate, (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one (DMP 266). Pharm Dev Technol. 1996; 1:91-5. http://www.ncbi.nlm.nih.gov/pubmed/9552335?dopt=AbstractPlus
5. Anon. Three new drugs for HIV infection. Med Lett. 1998; 40:114-6.
6. Spence RA, Kati WM, Anderson KS et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 1995; 267:988-93. http://www.ncbi.nlm.nih.gov/pubmed/7532321?dopt=AbstractPlus
9. Bacheler L, Weislow O, Snyder S et al. Virologic resistance to efavirenz. Int Conf AIDS. 1998; 12:287.
10. Winslow DL, Garber S, Reid C et al. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS. 1996; 10:1205-9. http://www.ncbi.nlm.nih.gov/pubmed/8883581?dopt=AbstractPlus
11. Merluzzi VJ, Hargrave KD, Labadia M et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990; 250:1411-13. http://www.ncbi.nlm.nih.gov/pubmed/1701568?dopt=AbstractPlus
12. De Clerq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 1998; 38:153-79. http://www.ncbi.nlm.nih.gov/pubmed/9754886?dopt=AbstractPlus
13. Tashima KT, Caliendo AM, Ahmad M et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients. J Infect Dis. 1999; 180:862-4. http://www.ncbi.nlm.nih.gov/pubmed/10438381?dopt=AbstractPlus
14. Graul A, Rabasseda J, Castaner J. Efavirenz. Drugs Future. 1998; 23:133-41.
15. Haas DW, Fessel WJ, Delapenha RA et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2001; 183:392-400. http://www.ncbi.nlm.nih.gov/pubmed/11133370?dopt=AbstractPlus
16. Staszewski S, Morales-Ramirez J, Tashima KT et al for the Study 006 Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999; 341:1865-73. http://www.ncbi.nlm.nih.gov/pubmed/10601505?dopt=AbstractPlus
17. Albrecht M, Katzenstein D, Bosch RJ et al. ACTG 364: virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new nucleoside analogs in nucleoside experienced subjects. Int Conf AIDS. 1998; 12:52.
18. Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001; 75:4999-5008. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=114903&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/11333879?dopt=AbstractPlus
19. Bacheler LT, Anton ED, Kudish P et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000; 44:2475-84. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=90088&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10952598?dopt=AbstractPlus
22. Freimuth WW. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chemother. 1996; 4:279-89.
23. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354:251-60. http://www.ncbi.nlm.nih.gov/pubmed/16421366?dopt=AbstractPlus
24. Fiske W, Benedek I, Brennan J et al. Pharmacokinetics of efavirenz in subjects with chronic liver disease. Sixth Conference on Retroviruses and Opportunistic Infections Chicago, IL 1999. Abstract No. 367. From web site. http://www.retroconference.org/1999
25. Fletcher CV, Brundage RC, Fenton T et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther. 2008; 83:300-6. http://www.ncbi.nlm.nih.gov/pubmed/17609682?dopt=AbstractPlus
30. Easterbrook PJ. Efavirenz. Drugs. 1998; 56:1065.
31. Conway B. Efavirenz. Drugs. 1998; 56:1065-6.
32. Hirsch MS, Conway B, D’Aquila RT et al. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA. 1998; 279:1984-91. http://www.ncbi.nlm.nih.gov/pubmed/9643863?dopt=AbstractPlus
40. Fiske W, Benedek IH, Joseph JL et al. Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers. Int Conf AIDS. 1998; 12:827.
41. Benedek I, Joshi A, Fiske WD et al. Virologic resistance to efavirenz. Int Conf AIDS. 1998; 12:829.
43. Yuen N (Agouron, La Jolla, CA): Personal communication; 1999 Mar 8.
45. Gallant J, Seekins D, Hicks C et al. A phase II, double-blind, placebo-control, dose-ranging study to assess the antiretroviral activity & safety of efavirenz (EFV, sustiva, DMP266) in combination with open-label zidovudine (ZDV) w/ lamivudine (3TC) at >48 weeks [DMP266-005]. Proceedings of 38th ICAAC San Diego, CA 1998. Abstracts-On-Disk. Abstract No. I-245.
47. Starr SE, Fletcher CV, Spector SA et al for the Pediatric AIDS Clinical Trials Group 382 Team. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med. 1999; 341:1874-81. http://www.ncbi.nlm.nih.gov/pubmed/10601506?dopt=AbstractPlus
50. Miller V, de Bethune MP, Kober A et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother. 1998; 42:3123-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=106010&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9835502?dopt=AbstractPlus
52. DuPont Pharmaceuticals, Wilmington, DE: Personal communication.
53. Reviewers’ comments (personal observations).
54. Benedek IH, Fiske WD, White SJ et al. Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers. Presented at 36th annual meeting of Infectious Disease Society of America, Denver, CO: 1998 Nov 12-15. Abstract No. 461.
57. Maserati R, Villani P, Seminari E et al. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS. 1999; 13:870-1. http://www.ncbi.nlm.nih.gov/pubmed/10357395?dopt=AbstractPlus
58. Vandamme AM, Van Laethem K, De Clercq E. Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs. 1999; 57:337-61. http://www.ncbi.nlm.nih.gov/pubmed/10193687?dopt=AbstractPlus
59. Villani P, Regazzi MB, Castelli F et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol. 1999; 48:712-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2014352&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10594473?dopt=AbstractPlus
60. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep. 1998; 47(No. RR-20).
61. Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Recomm Rep. 2000; 49:185-9.
62. Falloon J, Piscitelli S, Vogel S et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin Infect Dis. 2000; 30:313-8. http://www.ncbi.nlm.nih.gov/pubmed/10671334?dopt=AbstractPlus
63. Lumpkin MM, Alpert A. Risk of drug interactions with St. John’s wort and indinavir and other drugs. FDA Public Health Advisory. 2000 Feb 10. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052238.htm
64. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St. John’s wort. Lancet. 2000; 355:547-8. http://www.ncbi.nlm.nih.gov/pubmed/10683007?dopt=AbstractPlus
65. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St.John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999; 66:338-45. http://www.ncbi.nlm.nih.gov/pubmed/10546917?dopt=AbstractPlus
66. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John’s wort. Lancet. 2000; 355:548-9. http://www.ncbi.nlm.nih.gov/pubmed/10683008?dopt=AbstractPlus
67. Izzedine H, Aymard G, Launay-Vacher V et al. Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis. AIDS. 2000; 14:618-9. http://www.ncbi.nlm.nih.gov/pubmed/10780727?dopt=AbstractPlus
68. Podzamczer D, Consiglio E, Ferrer E et al. Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. AIDS. 2000; 14:331-2. http://www.ncbi.nlm.nih.gov/pubmed/10716515?dopt=AbstractPlus
71. American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infections. Am J Respir Crit Care Med. 2000; 161:S221-47.
75. DiCenzo R, Peterson D, Cruttenden K et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004; 48:4328-31. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=525398&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/15504860?dopt=AbstractPlus
76. Sevinsky H, Eley T, Persson A et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011; 16:149-56. http://www.ncbi.nlm.nih.gov/pubmed/21447863?dopt=AbstractPlus
77. Carten ML, Kiser JJ, Kwara A et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol. 2012; 2012:137192. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3299227&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22536010?dopt=AbstractPlus
78. Scarsi KK, Darin KM, Nakalema S et al. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Clin Infect Dis. 2016; 62:675-82. http://www.ncbi.nlm.nih.gov/pubmed/26646680?dopt=AbstractPlus
79. Perry SH, Swamy P, Preidis GA et al. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS. 2014; 28:791-3. http://www.ncbi.nlm.nih.gov/pubmed/24401645?dopt=AbstractPlus
175. AbbVie, Inc. Viekira XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets prescribing information. North Chicago, IL; 2016 Jul.
176. Gilead Sciences. Epclusa (sofosbuvir and velpatasvir) tablets prescribing information. Foster City, CA; 2016 Jun.
177. Merck & Co., Inc. Zepatier (elbasvir and grazoprevir) tablets prescribing information. Whitehouse Station, NJ; 2016 Jan.
178. Bristol-Myers Squibb Company. Daklinza (daclatasvir) tablets prescribing information. Princeton, NJ. 2016 Apr.
179. AbbVie, Inc. Technivie (ombitasvir, paritaprevir, and ritonavir) tablets prescribing information. North Chicago, IL; 2016 Jun.
180. AbbVie, Inc. Viekira Pak (ombitasvir, paritaprevir, and ritonavir copackaged with dasabuvir) tablets prescribing information. North Chicago, IL; 2016 Jun.
181. Gilead Sciences, Inc. Harvoni (ledipasvir and sofosbuvir) tablets prescribing information. Foster City, CA; 2016 Jun.
187. Janssen. Olysio (simeprevir) capsules prescribing information. Titusville, NJ; 2016 Feb.
188. Gilead Sciences, Inc. Sovaldi (sofosbuvir) prescribing information. Foster City, CA; 2015 Aug.
198. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – United States, 2016. From HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov
199. Kuhar DT, Henderson DK, Struble KA et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013; 34:875-92. http://www.ncbi.nlm.nih.gov/pubmed/23917901?dopt=AbstractPlus
200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (July 14, 2016). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov
201. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in pediatric HIV infection (April 26, 2016). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov
202. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States (October 26, 2016). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov
203. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules prescribing information. Princeton, NJ; 2016 Sep.
204. Janssen Therapeutics. Prezista (darunavir) oral suspension and tablets prescribing information. Titusville, NJ; 2016 Sep.
205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2016 Sep.
207. AbbVie Inc. Kaletra (lopinavir/ritonavir) tablets and oral solution prescribing information. North Chicago, IL; 2016 Sep.
208. ViiV Healthcare. Viracept (nelfinavir mesylate) tablets and oral powder prescribing information. Research Triangle Park, NC; 2012 Apr.
210. Genentech USA. Invirase (saquinavir mesylate) capsules and tablets prescribing information. South San Francisco, CA; 2016 Sep.
211. Boehringer Ingelheim. Aptivus (tipranavir) capsules and oral solution prescribing information. Ridgefield, CT; 2012 Apr.
212. ViiV Healthcare. Rescriptor (delavirdine mesylate) tablets prescribing information. Research Triangle Park, NC; 2010 Sep.
214. Janssen. Intelence (etravirine) tablets prescribing information. Raritan, NJ; 2012 Mar.
215. Boehringer Ingelheim. Viramune (nevirapine) tablets and oral suspension prescribing information. Ridgefield, CT; 2011 Nov.
221. Gilead Sciences. Viread (tenofovir disoproxil fumarate) tablets prescribing information. Foster City, CA; 2012 Jan.
223. Genentech USA. Fuzeon (enfuvirtide) for injection prescribing information. South San Francisco, CA; 2011 Aug.
224. ViiV Healthcare. Selzentry (maraviroc) tablets prescribing information. Research Triangle Park, NC; 2011 Nov.
225. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets, chewable tablets, and for oral suspension prescribing information. Whitehouse Station, NJ; 2015 Feb.
226. Janssen Therapeutics. Edurant (rilpivirine) tablets prescribing information. Titusville, NJ; 2015 Aug.
232. Bristol-Myers Squibb and Gilead Sciences. Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets prescribing information. Foster City, CA 2013 Oct.
236. ViiV Healthcare. TIVICAY (dolutegravir) tablets prescribing information. Research Triangle Park, NC; 2014 May.
238. Bristol-Myers Squibb. Evotaz (atazanavir/cobicistat) tablets prescribing information. Princeton, NJ; 2016 Jul.
239. Gilead Sciences. Tybost (cobicistat) tablets prescribing information. Foster City, CA; 2014 Sep.
Frequently asked questions
- What is the difference between HIV treatments Symfi and Symfi Lo?
- What drugs are contained in the HIV treatment Symfi Lo?
More about efavirenz
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (8)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: NNRTIs
- Breastfeeding
- En español